Research
Hormonal
SGLT2 inhibitors (specifically empagliflozin and canagliflozin) reduce major adverse cardiovascular events (MACE) in patients with Type 2 Diabetes, with empagliflozin also reducing heart failure hospitalizations.
If you have Type 2 Diabetes and heart risk, SGLT2 inhibitors like empagliflozin or canagliflozin can significantly lower your risk of heart attack, stroke, and heart failure hospitalization. These drugs work by removing excess sugar through urine. Discuss these with your doctor, especially if you have heart failure.
StrongSupportsVERY_HIGH confidence
After a median follow-up of 3.1 years, there was a 14% reduction in the 3-point major adverse cardiovascular event (MACE) in the active treatment group compared to placebo (HR 0.86, 95% CI 0.74 – 0.99; p¼0.04 for superiority)... a 17% reduction in the composite CV death or hospitalization for heart failure were seen in the dapagliflozin group (HR 0.83, 95% CI 0.73 – 0.95, p¼0.005)
Why this rating
Based on large RCTs (EMPA-REG, CANVAS, DECLARE-TIMI 58) with clear outcomes.
Source
A review of the evidence on cardiovascular outcomes from obesity treatment
Roshaida Abdul Wahab et al. · Obesity Pillars · 2023
narrative_reviewCited 17×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →